ArticleAmerican journal of translational research2023
Wuling capsules alleviate sleep disorders in patients receiving maintenance hemodialysis.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the clinical effect of Wuling capsules on sleep disorders in patients receiving maintenance hemodialysis.
methodsThe data of 114 end-stage renal disease patients with sleep disorders who received maintenance hemodialysis in JiuJiang hospital of traditional Chinese medicine between February 2020 and January 2022 were retrospectively analyzed. Among them, 60 patients treated with Wuling capsule were assigned to a research group, and the other 54 patients treated with estazolam were enrolled into a control group. The two groups were compared in terms of clinical efficacy and adverse reactions after treatment, as well as Pittsburgh sleep quality index (PSQI), fatigue state, and negative emotions before and after treatment.
resultsThe research group showed a significantly higher overall response rate than the control group, and presented a significantly lower total incidence of adverse reactions than the control group. After treatment, the research group exhibited notably lower scores of PSQI, and physical as well as mental fatigue than the control group. In addition, after treatment, the research group demonstrated evidently lower anxiety and depression scores than the control group. No significant difference was found in prognosis between the two groups after 6 months of treatment. An older age, longer duration of dialysis, lower albumin level, higher serum phosphorus, and skin pruritus were independent risk factors for unfavorable prognosis.
conclusionWuling capsules exhibited good efficacy and safety in the treatment of sleep disorders in patients receiving maintenance hemodialysis as compared to estazolam, so this capsule is worthy of further clinical application.
Indexed as
Identifiers
38074821PMC10703655W4389803177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.